Daxor Corporation to Present at the H.C. Wainwright 23rd Annual Global Investment Virtual Conference
07 Setembro 2021 - 9:30AM
Daxor Corporation (NYSE:DXR), the global leader in blood volume
measurement technology, today announces that President and Chief
Executive Officer Michael Feldschuh will present at the 23rd Annual
H.C. Wainwright Global Investment Conference which is being held
virtually from September 13-15, 2021.
Mr. Feldschuh will provide an overview of the
company’s latest news and updates on Daxor’s business model, growth
strategy, and next generation technology in his presentation which
will become available beginning on September 13th at 7:00 AM
ET.
Investors can register here:
www.hcwevents.com.
Mr. Feldschuh will be available for one-on-one
meetings throughout the conference.
Interested investors can contact Bret Shapiro at
COREIR either by calling 1-516-222-2560 or emailing
brets@coreir.com.
About Daxor
Corporation
Daxor Corporation (NYSE: DXR) is the global
leader in blood volume measurement technology focused on blood
volume testing innovation (organized as an investment company with
fully-owned innovative medical instrumentation and biotechnology
operations). We developed and market the BVA-100® (Blood Volume
Analyzer), the first diagnostic blood test cleared by the FDA to
provide safe, accurate, objective quantification of blood volume
status and composition compared to patient-specific norms. The BVA
technology enhances hospital performance metrics in a broad range
of surgical and medical conditions, including heart failure and
critical care, by informing treatment strategies, resulting in
significantly improved multiple measures of patient outcomes.
Daxor's mission is to advance healthcare by enabling optimal fluid
management with blood volume analysis. Daxor’s vision is optimal
blood volume for all. For more information, please visit our
website at Daxor.com.
Forward-Looking Statements
Certain statements in this release may include
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995, including without
limitation, statements regarding the impact of hiring sales staff
and expansion of our distribution channels. Forward-looking
statements are predictions, projections and other statements about
future events that are based on current expectations and
assumptions and, as a result, are subject to risks and
uncertainties. Many factors could cause actual future events to
differ materially from the forward-looking statements in this
release, including, without limitation, those risk associated with
our post-market clinical data collection activities, benefits of
our products to patients, our expectations with respect to product
development and commercialization efforts, our ability to increase
market and physician acceptance of our products, potentially
competitive product offerings, intellectual property protection,
FDA regulatory actions, our ability to integrate acquired
businesses, our expectations regarding anticipated synergies with
and benefits from acquired businesses, and additional other risks
and uncertainties described in our filings with the SEC.
Forward-looking statements speak only as of the date when made.
Daxor does not assume any obligation to publicly update or revise
any forward-looking statements, whether as a result of new
information, future events or otherwise.
Investor Relations Contact:Bret
ShapiroSr. Managing Partner, CORE
IR516-222-2560brets@coreir.com
Daxor (AMEX:DXR)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Daxor (AMEX:DXR)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024